AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT05343767 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Natural Wellness Low-Glu low dose
Description: The contents of 4 capsules of NW Low-Glu were equally distributed and inserted into 6 capsules size 0, and administered in 3 daily doses
Study NCT05343767 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Natural Wellness Low-Glu high dose
Description: The contents of 5 capsules of NW Low-Glu were equally distributed and inserted into 6 capsules size 0, and administered in 3 daily doses
Study NCT05343767 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Metformin
Description: A total dose of 2000 mg was administered per day.
Study NCT02711228 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Subcutaneous Immune Globulin (Human) (Hizentra)
Description: Hizentra, Subcutaneous Immune Globulin (Human) (SCIg), is a ready to use, polyvalent human normal Immunoglobulin G (IgG) for subcutaneous administration. Hizentra is a 20% IgG protein solution, is prepared from large pools of human plasma, and is stabilized by L-Proline.
Study NCT04235296 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: epidermal growth factor
Description: Residual wounds from the same person were divided into control group and experimental group. The epidermal growth factor is used to control group. Then the foam wound dressing was selected to cover the residual wound, and the dressing was changed every 2 days.
Study NCT04235296 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: mesenchymal stem cell conditioned medium-derived pleiotropic factor
Description: Residual wounds from the same person were divided into control group and experimental group. The pleiotropic factor is used to control group. Then the foam wound dressing was selected to cover the residual wound, and the dressing was changed every 2 days.
Study NCT03479333 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Short implant
Description: Short implant will be placed depending on the previous randomization. For that, a surgical access will be done, and the implant will be placed, cover screw will be installed and the access closed. The patient will receive the definitive crown after five months after the short implant installation.
Study NCT03479333 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Standard implant with sinus lift
Description: First, a surgical access will be performed, followed by sinus lift procedure. Next, a standard implant will be placed, cover screw will be installed and the access closed. The patient will receive the definitive crown after five months after the short implant installation.
Study NCT01110642 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lovastatin
Description: Topical lovastatin applied to red, rashy areas two times daily for 12 months
Study NCT02009540 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Botulinum toxin injected to bladder body
Description: arm will receive 100u of onaBoNT-A in 20x1ml aliquots (5u/ml). 20 injections will be given into the bladder wall, sparing the trigone. Injections will be given through all layers of the bladder eg suburothelially and intradetrusor. The intervention will be performed under local anaesthetic using a flexible cystoscope.
Study NCT02009540 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Botulinum toxin injected into trigone
Description: Arm B will receive 100u onaBoNT-A injected into 10x1ml suburothelial peri-trigonal sites (aliquot dose 10u/ml). The procedure will be performed under local anaesthetic by flexible cystoscopy.
Study NCT02508818 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Parabolic flight
Study NCT02508818 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Cardiovascular measurements
Study NCT00125528 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: D-cycloserine
Description: D-cycloserine 50 mg bid; D-cycloserine 100 mg bid; D-cycloserine 200 mg bid
Study NCT00125528 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: placebo bid
Study NCT04343105 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: pecto-intercostal plane block
Description: under ultrasound guidance, pecto-intercostal plane block will be performed between 3rd and 4th rib 2 cm lateral to sternal border in supine position at the interfascial plane between pectoralis major muscle and intercostal muscles
Study NCT04343105 — intervention group
Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: pecto-intercostal plane block
Description: under ultrasound guidance, pecto-intercostal plane block will be performed between 3rd and 4th rib 2 cm lateral to sternal border in supine position at the interfascial plane between pectoralis major muscle and intercostal muscles
Study NCT01307644 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Experimental: Web-based only (WO) weight intervention
Description: The WO intervention included evidence-based lifestyle modification for healthy eating and activity, with self-monitoring and goal setting, and messages based on constructs from the Health Promotion Model across 3 phases. The intent of the phases was to deliver more intensive intervention during Phase 1, transitioning to less intensive intervention during phase 2, to providing support for self managed weight maintenance during Phase 3.
Study NCT01307644 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Experimental: WO plus peer-led discussion board (WD)
Description: Includes WO intervention plus asynchronous discussion board managed by peer leader, whose identity is masked. The peer leader who posted theme-based messages, called primers, that were consistent with WO themes across phases.
Study NCT01307644 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Experimental: WO & professional email counseling (WE)
Description: Includes WO intervention plus professional email counseling provided by a registered dietitian whose identity is masked. The email counselor is responsible for reviewing eating, activity, weight logs, and goals on the web-site and send e-mail feedback, in addition to responding to email questions. The e-mail process will follow the 5A's Model for Behavioral Counseling (assess, advise, agree, assist, and arrange) that was adapted for this study.
Study NCT02236117 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Aerobic Training
Description: Will be included 160 children, 80 in an experimental group and 80 in a control group of both genders. The experimental group will realize aerobic training during 10 weeks (3×40min week-1; intensity, >80% maximal aerobic velocity - MAV), while the control group will have involved with the physical education classes two times a week for 50 minutes each class. The aerobic protocol will be composed by 2 sessions of intermittent running and 1 session by continuous.
Study NCT01510769 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lesinurad
Description: Tablets, 400 mg once daily (QD)
Study NCT01510769 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lesinurad
Description: Tablets, 200 mg QD
Study NCT01510769 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Tablets, Placebo QD
Study NCT01510769 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Febuxostat
Description: 80 mg
Study NCT01510769 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Febuxostat
Description: 80 mg
Study NCT02230917 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sotatercept
Study NCT02230917 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT01866085 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: AdVance® sling procedure
Study NCT01866085 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: ARGUS Sling procedure
Study NCT05306808 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: physiotherapy class
Description: The supervised 1-hour group exercise class will be conducted twice a week, with a maximum of 8 patients in each class. Subjects will be given a home log for exercise recording. If subjects are unable to attend exercise class for any reason (eg., low counts or feeling unwell, etc.), they will be advised to continue xercises at home. On the day of one of the exercise classes each week, there will be an additional 1-hour group education/ discussion session which may be conducted by PT, OT, APN, dietician or medical social worker. Topics covered will include physical activity, management of fatigue, lymphoedema, neuropathy, brain fog, return to work, stress, nutrition, sexuality, psychosocial and caregiver issues. There will be 10 sessions of educational class in total for each subject.
Study NCT00924859 — intervention group
Intervention type: OTHER
Intervention: ELISA Test
Description: assess the overall accuracy of D-dimer values and FXIII activation peptide (FXIII-AP), using a newly developed ELISA test
Study NCT02659748 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Milk Fat
Description: Three daily servings of whole yogurt (3.25% fat).
Study NCT02659748 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Control Fat
Description: Three daily servings of fat-free yogurt supplemented with a control fat.
Study NCT01119079 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Normal Saline
Description: 10ml Normal Saline instilled in the epidural space
Study NCT01119079 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Administration of epidural anesthesia for labor
Description: Standard procedure
Study NCT03113136 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Low wattage E cigarette device
Description: The low wattage E cigarette device will be provided to the participant and they will be instructed to vape ad libitum for 12 weeks and then be assessed at 6 months and 12 months for continued use of device.
Study NCT03113136 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: High wattage E cigarette device
Description: The high wattage E cigarette device will be provided to the participant and they will be instructed to vape ad libitum for 12 weeks and then be assessed at 6 months and 12 months for continued use of device.
Study NCT03113136 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Usual brand cigarette
Description: The usual brand of cigarettes will be provided to the participant and they will be instructed to smoke ad libitum for the duration of the study.
Study NCT00749047 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pioglitazone
Description: 15-45 mg/day
Study NCT00003497 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Antineoplaston therapy (Atengenal + Astugenal)
Description: Antineoplaston therapy (Atengenal + Astugenal) capsules orally six to seven times a day. Treatment continues in the absence of disease progression or unacceptable toxicity. absence of disease progression or unacceptable toxicity.
Study NCT03069105 — intervention group
Intervention type: OTHER
Intervention: Questionnaire
Description: Participants will complete paper and pencil or electronic questionnaires at the cancer center or in the privacy of their own homes.
Study NCT04306796 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: 3D printed splints
Description: 3D printed made to measure splints
Study NCT04306796 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Thermoplastic splints
Description: thermoplastic splints individually adjusted by occupational therapists
Study NCT03564704 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Dexamethasone will be added in Pre-phase Regimen, Induction-Regimen, Consolidation-Module of PDT-ALL-LBL protocol.
Study NCT03564704 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: vincristine
Description: Vincristine will be added to Induction-Regimen, Consolidation-Module and Maintenance-Module of PDT-ALL-LBL protocol.
Study NCT03564704 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: CTX will be added to Induction-Regimen, Consolidation-Module and Maintenance-Module of PDT-ALL-LBL protocol.
Study NCT03564704 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Idarubicin
Description: IDA will be added to Induction-Regimen and Consolidation-Module of PDT-ALL-LBL protocol.
Study NCT03564704 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pegaspargase
Description: PEG-ASP will be added to Induction-Regimen and Consolidation-Module of PDT-ALL-LBL protocol.
Study NCT03564704 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Adriamycin
Description: Adriamycin will be added to Consolidation-Module of PDT-ALL-LBL protocol.
Study NCT03564704 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methotrexate
Description: Methotrexate will be added to Consolidation-Module of PDT-ALL-LBL protocol.
Study NCT03564704 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 6-mercaptopurine.
Description: Mercaptopurine will be added to Consolidation-Module and Maintenance-Module of PDT-ALL-LBL protocol.
Study NCT03564704 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etoposide
Description: VP-16 will be added to Consolidation-Module of PDT-ALL-LBL protocol.
Study NCT03564704 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cytarabine
Description: AraC will be added to Consolidation-Module of PDT-ALL-LBL protocol.
Study NCT03564704 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Bone marrow aspiration
Description: Bone marrow aspiration and additional tests will be performed in all module of PDT-ALL-LBL protocol.
Study NCT01480297 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Salsalate
Description: Salsalate 3 grams daily (1 gram TID with meals)
Study NCT03126760 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acthar Gel
Description: Acthar Gel 1 mL (80U) for subcutaneous injection
Study NCT03126760 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo for subcutaneous injection
Study NCT01535365 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Heat
Description: Application of heat pack to the back or neck sprain.
Study NCT01535365 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Cold
Description: Application of ice pack to the back or neck sprain.
Study NCT02326870 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: AutoLap
Study NCT01951469 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gefitinib and Pemetrexed/platinum
Description: Gefitinib 250mg is Taken Orally on day 1-28,combined Pemetrexed (D1)+cisplatin (D1-3) or Pemetrexed (D1) + nedaplatin (D1) chemotherapy, every 28 days
Study NCT01951469 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Gefitinib mono-therapy
Description: Gefitinib 250mg is Taken Orally everyday
Study NCT03556930 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: AlignRT system (VisionRT LTD, UK)
Description: Pediatric patient will watch age-proper movie during radiation treatment. The motion of pediatric patient will continually be monitored by an AlignRT system (VisionRT LTD, UK). Both movie and radiation beam will be paused if the motion of pediatric patient is beyond positioning accuracy threshold. Movie and beam will be resumed if pediatric patient is positioning with in tolerance.
Study NCT01008280 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: baclofen
Description: baclofen 10 mg tid
Study NCT01008280 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: placebo pill tid
Study NCT01363986 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: trastuzumab [Herceptin]
Description: Initial loading dose of 4 mg/kg i.v. infusion, followed by weekly doses of 2 mg/kg for up to 18 weeks.
Study NCT01780610 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Letrozole and human chorionic gonadotrophin
Description: the follicular development is supported by Letrozole(LE) 2.5mg,once daily is introduced on cycle day 3 .And on cycle day 10 , a Vagina ultrasound is introduced to monitor the development of the follicular ,following by intramuscular gonadotrophin 37.5\~75 IU/d until there is a Luteinizing Hormone(LH) surge or ovulation .On the day appearing Luteinizing Hormone surge，patients is always introduced intramuscular human chorionic gonadotrophin(HCG) 10000 IU.If there is sill no Luteinizing Hormone surge when the follicle is 20-24mm ,the ovulation will be induced by HCG.Then the luteum was supported by HCG 2000-2500 IU/3d.Transfer of thawed embryos will be performed 3 days after ovulation is observed.
Study NCT01780610 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: estradiol and progesterone
Description: oral estradiol, 2 mg, once daily, was introduced on cycle day 3 with an increasing doses protocol. If the endometrial thickness was greater than 7mm, progesterone 40-60 mg in oil was administered via intramuscular injection. Transfer of thawed embryos was performed 3 days later
Study NCT00130832 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Rotavirus Vaccine, Live, Oral, Pentavalent
Description: Three doses of rotavirus vaccine, live, oral, pentavalent. Dose 1 was given on Day 1, Dose 2 was given 56 to 84 days post Dose 1, and Dose 3 was given 56 to 84 days post Dose 2.
Study NCT00130832 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Comparator: Oral Poliovirus Vaccine (OPV)
Description: Three doses OPV. Dose 1 was given on Day 1, Dose 2 was given 56 to 84 days post Dose 1, and Dose 3 was given 56 to 84 days post Dose 2.
Study NCT00130832 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Comparator: Oral Poliovirus Vaccine (OPV) (staggered)
Description: Three doses OPV. Dose 1 was given 14 to 28 days post Dose 1 of RotaTeq, Dose 2 was given 14 to 28 days post Dose 2 of RotaTeq, and Dose 3 was given 14 to 28 days post Dose 3 of RotaTeq.
Study NCT01207973 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 113823
Description: 5 dose-groups of multiple oral doses of BI 113823
Study NCT02881268 — intervention group
Intervention type: OTHER
Intervention: blood sample
Study NCT03564704 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Intrathecal injection
Description: Intrathecal injection of chemotherapy will be performed in PDT-ALL-LBL protocol.
Study NCT03564704 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation therapy
Description: Radiation therapy will be performed for mediastinum and/or central nervous system leukemia/lymphoma in PDT-ALL-LBL protocol.
Study NCT03564704 — intervention group
Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: NGS
Description: Next-Generation-Sequencing (NGS) will be performed in PDT-ALL-LBL protocol.
Study NCT03564704 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: allogeneic hematopoietic stem cell transplantation
Description: Allo-HSCT will be added to LBL patients with available donor in PDT-ALL-LBL protocol.
Study NCT03564704 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Flow-MRD
Description: Flow-MRD will be added to PDT-ALL-LBL for bone marrow and cerebrospinal fluid samples.
Study NCT03564704 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: FISH
Description: FISH will be added to PDT-ALL-LBL for bone marrow samples.
Study NCT03564704 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Flow immunophenotyping
Description: Flow immunophenotyping will be performed in PDT-ALL-LBL protocol.
Study NCT03564704 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Karyotyping
Description: Karyotyping will be performed in PDT-ALL-LBL protocol.
Study NCT03564704 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chidamide
Description: HDACi chidamide will be added to induction regimen, consolidation and maintenance module of PDT-ALL-LBL.
Study NCT03564704 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: PET-CT scan
Description: PET-scan will be performed for T-LBL patients for MRD assessment in PDT-ALL-LBL.
Study NCT04357223 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: extract from Angelica archangelica leaf
Description: A standardized extract from Angelica archangelica leaf. Capsule, Twice Daily
Study NCT04357223 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study NCT02585336 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Brief intervention
Description: An interviewer provides health information, elicits motivation to reduce SSB consumption, and helps participants make implementation plans. Booster phone calls occur at 1 week after the intervention visit, and at 2 weeks and 24 weeks following the date on which SSBs sales ended at the participant's work location.
Study NCT04345367 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Abrocitinib 200 mg
Description: Abrocitinib 200 mg administered as two 100 mg tablets to be taken orally once daily for 26 weeks. Placebo injections will be administered every other week for 24 weeks.
Study NCT04345367 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: ACTIVE_COMPARATOR
Intervention: Dupilumab 300 mg
Description: Dupilumab 300 mg administered as a single subcutaneous injection every other week for 24 weeks (2 injections on day 1). Placebo tablets will be administered daily.
Study NCT02664571 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Pet scan with FBB
Description: Patients will have a pet scan with Florbetaben (NEURACEQ : FBB). All other care corresponds to routine care.~Florbetaben is used during pet scans to visualize beta amyloid plaques and cannot be a separate intervention in and of itself.